For the future of every childs vision.

Lead Product Candidates

Our late-stage phase 3 drug – 7MX – provides unique therapeutic options for millions of diagnosed but untreated or undertreated myopia in children.

Are you a Healthcare Practitioner ?

Learn more about myopia & how to treat it.

Meet us at

Theialife article is published in the British Journal of Ophthalmology

Theialife is featured on the front cover of the coveted British Journal of Ophthalmology
To learn more about the groundbreaking benefits of 7-Methyl-Xanthine in the use of Myopia control and treatment in children, The British journal of Ophthalmology published a peer-reviewed article.

August 22, 2022

Read more

Theialife is featured in the International Journal of Ophthalmology

Theialife article is published in the International Journal of Ophthalmology
Read our latest article on the “Role of 7-methylxanthine in myopia prevention and control: a mini-review”

January 31, 2023